Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: A randomised, parallel group, double-blind, exploratory study

European Journal of Dermatology

Volumn 20, Issue 4, 2010, Pages 465-471

  Fleming, Colin ^a   Ganslandt, Cecilia ^b   Guenther, Lyn ^c   Johannesson, Anders ^d   Buckley, Colin ^e   Simon, Jan C ^f   Stegmann, Helen ^b   Vestergaard Tingleff, Lotte ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b LEO PHARMA A S   (Denmark)

^c Guenther Dermatology Research Centre   (Canada)

^d Vällingby Läkarhus   (Sweden)

^e WATERFORD REGIONAL HOSPITAL   (Ireland)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Betamethasone dipropionate; Calcipotriol; Combination therapy; Psoriasis vulgaris

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; DRUG VEHICLE; ANTIINFLAMMATORY AGENT; BETAMETHASONE; CALCITRIOL; DERMATOLOGICAL AGENT; DRUG COMBINATION; GEL; IMMUNOGLOBULIN A; OINTMENT;

ADULT; ALOPECIA; APPLICATION SITE BURNING; APPLICATION SITE INFLAMMATION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; ARTHRALGIA; ARTICLE; BLISTER; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ECZEMA; ERYTHEMA; FEMALE; FOLLICULITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SKIN BURNING SENSATION; SKIN FISSURE; SKIN PAIN; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; EUROPE; GEL; MIDDLE AGED; OINTMENT; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; CALCITRIOL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EUROPE; FEMALE; GELS; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; OINTMENTS; PROSPECTIVE STUDIES; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VEHICLES; PHARMACEUTICAL VEHICLES;

EID: 77954742773     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.0948     Document Type: Article

References (23)

1. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and Treatment of Psoriasis in the United Kingdom. Arch Dermatol 2005; 141: 1537-41.
2. Schäfer T. Epidemiology of Psoriasis. Dermatology 2006; 212: 327-37.
3. Gottlieb AB. Psoriasis. Dis Manag Clin Outcomes 1998; 1: 195-202.
4. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004; 51: 704-8.
5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol 2009; 60: 643-59.
6. van de Kerkhof PCM, Barker J, Griffiths CEM, et al. Psoriasis: consensus on topical therapies. JEADV 2008; 22: 859-70.
7. Koo JY. Current consensus and update on psoriasis therapy: A perspective from the U.S. J Dermatol 1999; 26: 723-33.
8. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002; 146: 351-64.
9. UK Summary of Product Characteristics for Dovonex ointment. April 2007.
10. Guenther L, van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (one or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316-23.
11. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389-93.
12. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48: 48-54.
13. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82: 131-5.
14. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-60.
15. Tyring S, Bibby A, Foster R. A 52-week study of a calcipotriol/ betamethasone dipropionate scalp formulation and ointment in the treatment of psoriasis of the scalp and trunk/limbs in hispanic/latino and black/african American patients. In: 17th Congress of the European Academy of Dermatology and Venereology, Paris, 2008: abstracts: Abstr. no. FP1455.
16. Claréus BW, Houwing R, Sindrup JH, Wigchert S. The DESIRE study - psoriasis patients' satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice. Eur J Dermatol 2009; 19: 1-5.
17. Jemec GBE, Ganslandt C, Ortonne J-P, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trial. J Am Acad Dermatol 2008; 59: 455-63.
18. van der Kerkhof PCM, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: A randomized, double-blind, controlled trial. Br J Dermatol 2008; 160: 170-6.
19. Fredriksson T, Pettersson U. Severe psoriasis - Oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44. (Pubitemid 8387357)
20. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003; 4: 221-4.
21. Jemec GBE, Wulf HC. The greasiness of moisturisers. J Soc Cosmet Chem 1998; 49: 175-81.
22. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004; 150: 1167-73.
23. Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008; 217: 321-8.